Several types of leukemia cases have been reported, in which Chronic Myeloid Leukemia (CML) plays an important role. CML is developed due to the reciprocal translocation of chromosome 9 and chromosome 22 [t(9;22)(q34;q11)] and resistant mutation on ABL1 gene. It can be controlled by several techniques. In this study, we are focusing on the development of CML through the formation of Philadelphia chromosome and also the development of resistant mutation(s) against TKIs. CML can’t be cured but can be minimized the kinase production and maximize the life expectancy nowadays with the treatment of tyrosine kinase inhibitors (TKIs) therapy. But point mutations develop resistance against TKIs which is a big challenge to overcome. Multiple studies showed that T315I is the most frequently occurring mutation in the BCR-ABL1 gene. To overcome this problem, new drugs for e.g. Asciminib